| 0.207% |
| 1.59% |
| 4 | Quadrature Capital Ltd | 41K | $10.9M | — | 0.066% | 0.09% |
| 5 | Ninepoint Partners LP | 5K | $1.2M | — | 0.009% | 0.05% |
| 6 | FERGUSON WELLMAN CAPITAL MANAGEMENT, INC | 3K | $693K | 0.0% | 0.004% | 0.01% |
| 7 | DEARBORN PARTNERS LLC | 1K | $347K | 0.0% | 0.002% | 0.01% |
| 8 | E Fund Management (Hong Kong) Co., Ltd. | 84 | $22K | +40.0% | 0.000% | 0.01% |
| 9 | IFP Advisors, Inc | 14 | $3K | +16.7% | 0.000% | 0.00% |
| 10 | HUNTINGTON NATIONAL BANK | 1 | $244 | 0.0% | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in ASND — a direct measure of their conviction.
| 104.00% |
| +1.97 pp |
| $8.94B |
| +17% |
| Q4 2024 | 210 | 2.3% | 102.03% | +0.95 pp | $7.64B | 8.6% |
| Q3 2024 | 215 | — | 101.08% | — | $8.36B | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
2 institutions opened new positions in ASND during Q2 2026, while 264 fully exited. 7 added to existing positions and 0 trimmed.
ASND institutional ownership fell by 89.57 percentage points quarter-over-quarter, with a net change of -264 holders.
The top 10 institutions account for 100.0% of all reported 13F value in ASND, and the top 25 account for 100.0%.
Across the largest Rare Disease Biotech peers, institutional ownership levels are: IRLA (23.9%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.